Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 3, 2008 - Issue 1
Submit an article Journal homepage
95
Views
18
CrossRef citations to date
0
Altmetric
Reviews

Huprines for Alzheimer's disease drug development

Diego Muñoz-Torrero Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Diagonal, 643, E-08028-Barcelona, Spain +34 934024533; +34 934035941; [email protected]+34 934024536; +34 934035941; [email protected]
&
Pelayo Camps Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Av. Diagonal, 643, E-08028-Barcelona, Spain +34 934024533; +34 934035941; [email protected]+34 934024536; +34 934035941; [email protected]
Pages 65-81 | Published online: 19 Dec 2007

Bibliography

  • Wimo A, Winblad B, Aguero Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63-7
  • Mount C, Dowton C. Alzheimer disease: progress or profit? Nat Med 2006;12:780-4
  • Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Ann Rev Med 2006;57:513-33
  • Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977:189
  • Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17
  • Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6
  • Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006;129:2840-55
  • Castellani RJ, Zhu X, Lee H-G, et al. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother 2007;7:473-85
  • Lee H-G, Zhu X, Nunomura A, et al. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006;3:75-80
  • Sambamurti K, Suram A, Venugopal C, et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 2006;81-91
  • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's diasese: progress and problems on the road to therapeutics. Science 2002;297:353-6
  • Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006;3:71-3
  • Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-2
  • Saido TC, Iwata N. Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 2006;54:235-53
  • Skovronsky DM, Lee VM-Y, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Ann Rev Pathol Mech Dis 2006;1:151-70
  • Tschäpe J-A, Hartmann T. Therapeutic perspectives in Alzheimer's disease. Recent Pat CNS Drug Discov 2006;1:119-27
  • Verhoeff NPLG. Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer's disease. Expert Rev Neurother 2005;5:277-84
  • Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2004;10:3111-19
  • Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S12-S18
  • Colombres M, Sagal JP, Inestrosa NC. Overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr Pharm Des 2004;10:3121-30
  • Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S8-S11
  • Mori E, Hashimoto M, Krishnan K, Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease. Support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S19-S26
  • Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimer's Dementia 2006;2:118-25
  • Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676-82
  • Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991;253:872-9
  • Wermuth CG. The practice of medicinal chemistry. London: Academic Press, 2003
  • Proctor GR, Harvey AL. Synthesis of tacrine analogues and their structure–activity relationships. Curr Med Chem 2000;7:295-302
  • Kozikowski AP, Tückmantel W. Chemistry, pharmacology and clinical efficacy of the Chinese nootropic agent huperzine A. Acc Chem Res 1999;32:641-50
  • Tang XC, He XC, Bai DL. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Future 1999;24:647-63
  • Gregor VE, Emmerling MR, Lee C, Moore CJ. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex) derivatives. Bioorg Med Chem Lett 1992;2:861-4
  • Raves ML, Harel M, Pang Y-P, et al. 3D structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997;4:57-63
  • Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031-5
  • Pang Y-P, Quiram P, Jelacic T, et al. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996;271:23646-9
  • Pang Y-P, Hong F, Quiram P, et al. Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. J Chem Soc Perkin Trans I 1997;171-6
  • Carlier PR, Han YF, Chow ES-H, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999;7:351-7
  • Harel M, Quinn DM, Nair HK, et al. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J Am Chem Soc 1996;118:2340-6
  • Doucet-Personeni C, Bentley PD, Fletcher RJ, et al. A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem 2001;44:3203-15
  • Dvir H, Wong DM, Harel M, et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamics correlates. Biochemistry 2002;41:2970-81
  • Camps P, El Achab R, Font-Bardia M, et al. Easy synthesis of 7-alkylbicyclo[3.3.1]non-6-en-3-ones by silical gel-promoted fragmentation of 3-alkyl-2-oxaadamant-1-yl mesylates. Tetrahedron 1996;52:5867-80
  • Badia A, Baños JE, Camps P, et al. Synthesis and evaluation of tacrine–huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorg Med Chem 1998;6:427-40
  • Camps P, Contreras J, Morral J, et al. Synthesis of an 11-unsubstituted analogue of (±)-huperzine A. Tetrahedron 1999;55:8481-96
  • Camps P, Contreras J, El Achab R, et al. New syntheses of rac-huperzine A and its rac-7-ethyl-derivative. Evaluation of several huperzine A analogues as acetylcholinesterase inhibitors. Tetrahedron 2000;56:4541-53
  • Camps P, Muñoz-Torrero D. Tacrine–huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini Rev Med Chem 2001;1:163-74
  • Camps P, Gómez E, Muñoz-Torrero D, et al. Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors. J Med Chem 2001;44:4733-6
  • Camps P, El Achab R, Görbig DM, et al. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine–huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J Med Chem 1999;42:3227-42
  • Steinberg GM, Mednick ML, Maddox J, et al. A hydrophobic binding site in acetylcholinesterase. J Med Chem 1975;18:1056-61
  • Camps P, El Achab R, Morral J, et al. New tacrine–huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 2000;43:4657-66
  • Savini L, Campiani G, Gaeta A, et al. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett 2001;11:1779-82
  • Camps P, Contreras J, Font-Bardia M, et al. Enantioselective synthesis of tacrine–huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by X-ray diffraction analysis. Tetrahedron: Asymmetry 1998;9:835-49
  • Camps P, Cusack B, Mallender WD, et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000;57:409-17
  • Alcalá MM, Vivas NM, Hospital S, et al. Characterisation of the anticholinesterase activity of two new tacrine–huperzine A hybrids. Neuropharmacology 2003;44:749-55
  • Wang R, Yan H, Tang X-C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006;27:1-26
  • Perry EK, Smith CJ, Court JA, et al. Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 1988;91:211-16
  • Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 1998;62:131-40
  • Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989;24:276-85
  • Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid (1 – 40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004;360:21-4
  • Roman S, Vivas NM, Badia A, Clos MV. Interaction of a new potent anticholinesterasic compound (±)huprine X with muscarinic receptors in rat brain. Neurosci Lett 2002;325:103-6
  • Alcalá MM, Maderuelo A, Vivas NM, et al. Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors. Neurosci Lett 2005;379:106-9
  • Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 1997;8:963-8
  • Wang X-D, Chen X-Q, Yang H-H, Hu G-Y. Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex. Neurosci Lett 1999;272:21-4
  • Canudas AM, Pubill D, Sureda FX, et al. Neuroprotective effects of (±)-huprine Y on in vitro and in vivo models of excitotoxicity damage. Exp Neurol 2003;180:123-30
  • Jordá EG, Verdaguer E, Jiménez A, et al. (±)-Huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration. J Alzheimer Dis 2004;6:577-83
  • Alvarez A, Bronfman F, Pérez CA, et al. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides. Neurosci Lett 1995;201:49-52
  • Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91
  • Alvarez A, Alarcón R, Opazo C, et al. Stable complexes involving acetylcholinesterase and amyloid-β-peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998;18:3213-23
  • Reyes AE, Chacón MA, Dinamarca MC, et al. Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus. Effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol 2004;164:2163-74
  • De Ferrari GV, Canales MA, Shin I, et al. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001;40:10447-57
  • Pan KM, Baldwin M, Nguyen J, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993;90:10962-6
  • Schwarze-Eicker K, Keyvani K, Gortz N, et al. Prion protein (PrPc) promotes β-amyloid plaque formation. Neurobiol Aging 2005;26:1177-82
  • Armstrong RA, Lantos PL, Cairns NJ. Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology 2001;21:266-71
  • Pera M, Román S, Ratia M, et al. Acetylcholinesterase triggers the aggregation of PrP 106-126. Biochem Biophys Res Commun 2006;346:89-94
  • Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-Amyloid aggregation induction by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003;65:407-16.
  • Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem 2003;10:2231-52
  • Farlow M, Gracon SI, Heshey LA, et al. A controlled trial of tacrine in Alzheimer's patients. JAMA 1992;268:2523-9
  • Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993;46:13-20
  • Nassar A-EF, Kamel AM, Clarimont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov Today 2004;9:1055-64
  • Ma XC, Xin J, Wang HX, et al. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol Sin 2003;24:247-50
  • Medichem SA. Nuevos compuestos aminopiridínicos policíclicos inhibidores de acetilcolinesterasa, procedimiento para su preparación y su utilización. ES2100129 (1995); Novel polycyclic aminopyridine compounds as acetylcholinesterase inhibitors, preparation process and use thereof. WO97/13754 (1997)
  • Dvir H, Jiang HL, Wong DM, et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 2002;41:10810-18
  • Camps P, Gómez E, Muñoz-Torrero D, et al. Synthesis of diastereomeric 13-amido-substituted huprines as potential high affinity acetylcholinesterase inhibitors. Tetrahedron 2003;59:4143-51
  • Camps P, Gómez E, Muñoz-Torrero D. Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis. Tetrahedron 2004;60:5423-31
  • Camps P, Gómez E, Muñoz-Torrero D, et al. Binding of 13-amidohuprines to acetylcholinesterase: exploring the ligand-induced conformational change of the Gly117–Gly118 peptide bond in the oxyanion hole. J Med Chem 2006;49:6833-40
  • Fuxreiter M, Warshel A. Origin of the catalytic power of acetylcholinesterase: computer simulation studies. J Am Chem Soc 1998;120:183-94
  • Muñoz-Torrero D, Camps P. Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 2006;13:399-422
  • Muñoz-Ruiz P, Rubio L, García-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 2005;48:7223-33
  • Bolognesi ML, Andrisano V, Bartolini M, et al. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation. J Med Chem 2005;48:24-7
  • Rosini M, Andrisano V, Bartolini M, et al. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005;48:360-3
  • Belluti F, Rampa A, Piazzi L, et al. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced β-amyloid aggregation. J Med Chem 2005;48:4444-56
  • Cavalli A, Bolognesi ML, Capsoni S, et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed 2007;46:3689-92
  • Bolognesi ML, Banzi R, Bartolini M, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem 2007;50:4882-97
  • Piazzi L, Cavalli A, Belluti F, et al. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromemone (AP2238) derivatives. J Med Chem 2007;50:4250-4
  • Kwon YE, Park JY, No KT, et al. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1 – 42 aggregation for Alzheimer's disease therapeutics. Bioorg Med Chem 2007;15:6596-607
  • Hu M-K, Wu L-J, Hsiao G, Yen MH. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J Med Chem 2002;45:2277-82
  • Rodríguez-Franco MI, Fernández-Bachiller MI, Pérez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006;49:459-62
  • Camps P, Formosa X, Muñoz-Torrero D, et al. Synthesis and pharmacological evaluation of huprine–tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem 2005;48:1701-4
  • Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2005;9:1-24
  • Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50:433-40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.